NASDAQ:MNLO - Menlo Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.94 +0.04 (+0.58 %)
(As of 11/13/2018 11:37 AM ET)
Previous Close$6.90
Today's Range$6.66 - $7.37
52-Week Range$5.40 - $39.86
Volume4,169 shs
Average Volume106,308 shs
Market Capitalization$170.76 million
P/E Ratio-1.16
Dividend YieldN/A
BetaN/A
Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials to treat pruritus associated with psoriasis, atopic dermatitis, and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.

Receive MNLO News and Ratings via Email

Sign-up to receive the latest news and ratings for MNLO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNLO
Previous Symbol
CUSIPN/A
Phone650-486-1416

Debt

Debt-to-Equity RatioN/A
Current Ratio19.16
Quick Ratio19.16

Price-To-Earnings

Trailing P/E Ratio-1.16
Forward P/E Ratio-2.51
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.58 million
Price / Sales35.20
Cash FlowN/A
Price / CashN/A
Book Value($2.60) per share
Price / Book-2.67

Profitability

EPS (Most Recent Fiscal Year)($5.69)
Net Income$-29,070,000.00
Net Margins-268.61%
Return on Equity-41.70%
Return on Assets-30.31%

Miscellaneous

Employees32
Outstanding Shares23,230,000
Market Cap$170.76 million
OptionableNot Optionable

Menlo Therapeutics (NASDAQ:MNLO) Frequently Asked Questions

What is Menlo Therapeutics' stock symbol?

Menlo Therapeutics trades on the NASDAQ under the ticker symbol "MNLO."

How were Menlo Therapeutics' earnings last quarter?

Menlo Therapeutics Inc (NASDAQ:MNLO) released its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.33. Menlo Therapeutics had a negative return on equity of 41.70% and a negative net margin of 268.61%. View Menlo Therapeutics' Earnings History.

When is Menlo Therapeutics' next earnings date?

Menlo Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for Menlo Therapeutics.

What price target have analysts set for MNLO?

7 analysts have issued 1-year target prices for Menlo Therapeutics' stock. Their predictions range from $7.00 to $48.00. On average, they anticipate Menlo Therapeutics' stock price to reach $27.3333 in the next twelve months. This suggests a possible upside of 293.9% from the stock's current price. View Analyst Price Targets for Menlo Therapeutics.

What is the consensus analysts' recommendation for Menlo Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Menlo Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Menlo Therapeutics.

What are Wall Street analysts saying about Menlo Therapeutics stock?

Here are some recent quotes from research analysts about Menlo Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, ". After a solid quarter of execution in 3Q18, we reiterate our OW rating and 12-month price target of $25 for MNLO shares. We continue to believe that upward earnings revisions and multiple expansion will drive the stock higher. A greater appreciation for the company’s multiple indication approach for serlopitant will increase earnings estimates to levels not yet reflected in consensus expectations, in our view." (11/7/2018)
  • 2. According to Zacks Investment Research, "Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California. " (10/12/2018)

Has Menlo Therapeutics been receiving favorable news coverage?

Headlines about MNLO stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Menlo Therapeutics earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.

Who are some of Menlo Therapeutics' key competitors?

Who are Menlo Therapeutics' key executives?

Menlo Therapeutics' management team includes the folowing people:
  • Mr. Steven L. Basta, Pres, CEO & Director (Age 52)
  • Ms. Kristine M. Ball CPA, Sr. VP of Corp. Strategy & CFO (Age 46)
  • Dr. Paul S. Kwon M.D., Chief Scientific Officer (Age 47)
  • Mr. Stuart D. Sedlack M.B.A., VP of Bus. Devel. (Age 53)
  • Dr. Xiaoming Zhang Ph.D., Sr. VP of Non-Clinical & Pharmaceutical Devel. (Age 54)

When did Menlo Therapeutics IPO?

(MNLO) raised $86 million in an initial public offering on Thursday, January 25th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies, Piper Jaffray and Guggenheim Securities served as the underwriters for the IPO and JMP Securities was co-manager.

Who are Menlo Therapeutics' major shareholders?

Menlo Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include First Manhattan Co. (4.12%), JPMorgan Chase & Co. (2.60%), BlackRock Inc. (2.30%), Trexquant Investment LP (0.07%) and Virtu Financial LLC (0.06%). Company insiders that own Menlo Therapeutics stock include Presidio Partners 2007 Gp, LP and Vivo Capital Surplus Fund Viii. View Institutional Ownership Trends for Menlo Therapeutics.

Which institutional investors are buying Menlo Therapeutics stock?

MNLO stock was bought by a variety of institutional investors in the last quarter, including First Manhattan Co., JPMorgan Chase & Co., BlackRock Inc., Trexquant Investment LP and Virtu Financial LLC. View Insider Buying and Selling for Menlo Therapeutics.

How do I buy shares of Menlo Therapeutics?

Shares of MNLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Menlo Therapeutics' stock price today?

One share of MNLO stock can currently be purchased for approximately $6.94.

How big of a company is Menlo Therapeutics?

Menlo Therapeutics has a market capitalization of $170.76 million and generates $4.58 million in revenue each year. The company earns $-29,070,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Menlo Therapeutics employs 32 workers across the globe.

What is Menlo Therapeutics' official website?

The official website for Menlo Therapeutics is http://www.menlotherapeutics.com.

How can I contact Menlo Therapeutics?

Menlo Therapeutics' mailing address is 200 CARDINAL WAY 2ND FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-486-1416 or via email at [email protected]


MarketBeat Community Rating for Menlo Therapeutics (NASDAQ MNLO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  92
MarketBeat's community ratings are surveys of what our community members think about Menlo Therapeutics and other stocks. Vote "Outperform" if you believe MNLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel